Vect-Horus Enters License Agreement With Ionis Pharmaceuticals For Systemic Delivery Of RNA-Targeted Medicines For Neurological Diseases; Vect-Horus Receives Double-Digit Million-Dollar Upfront Payment; Eligible For Milestone Payments And Royalties
Portfolio Pulse from Benzinga Newsdesk
Vect-Horus has signed a license agreement with Ionis Pharmaceuticals for the systemic delivery of RNA-targeted medicines for neurological diseases. Vect-Horus has received a double-digit million-dollar upfront payment and is eligible for milestone payments and royalties.
January 30, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals has entered into a licensing agreement with Vect-Horus for RNA-targeted medicines, with Vect-Horus receiving a significant upfront payment and potential future payments.
The agreement with Vect-Horus could potentially expand Ionis Pharmaceuticals' portfolio in neurological treatments, which is a positive development. The upfront payment indicates a strong commitment and belief in the partnership's potential. This news is likely to be viewed positively by investors, potentially leading to a short-term increase in Ionis' stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80